Skip to main content
Assets
Intuitive Surgical logo
ISRG.NASDAQ
Intuitive Surgical
Health Care · Health Care Equipment

Robotic-assisted surgery company known for the da Vinci Surgical System and minimally invasive procedure platforms.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Intuitive Surgical.

Historical AI Opinions

Intuitive Surgical, Inc. (ISRG.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+91.7%

ISRG.NASDAQ does not currently pay dividends

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.93.05367.99642.93917.871.19KNov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$618+7.7%Not Generated this time
$666+16.0%Not Generated this time
$714+24.3%Not Generated this time
$765+33.3%Not Generated this time
$818+42.5%Not Generated this time
$874+52.2%Not Generated this time
$929+61.8%Not Generated this time
$987+72.0%Not Generated this time
$1,044+81.8%Not Generated this time
$1,101+91.8%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Intuitive Surgical maintains its dominant market leadership, leveraging its vast installed base, extensive surgeon training ecosystem, and robust intellectual property portfolio. Procedure volume grows steadily in the low-to-mid teens annually, fueled by an aging global population and the ongoing secular shift towards minimally invasive surgery. International expansion provides a consistent, long-term growth tailwind, while the Ion platform for lung biopsy becomes a significant contributor. Competition emerges but remains a secondary factor, unable to displace ISRG's entrenched position. The company's valuation remains at a premium, supported by consistent double-digit revenue growth and high profitability. The stock price appreciates in line with its strong, albeit moderating, earnings growth over the forecast period.

2. Scenarios & Signals

2.1. Bull Case

Intuitive Surgical's growth accelerates beyond expectations, driven by rapid adoption of its next-generation da Vinci and Ion platforms in international markets, particularly China and Western Europe. Favorable reimbursement policies and successful expansion into new, complex surgical procedures significantly increase the total addressable market. Competitors fail to gain meaningful traction, solidifying ISRG's monopoly-like status. A strong macroeconomic environment with lower interest rates boosts hospital capital expenditures, leading to a surge in system placements. This combination of superior execution and a favorable market backdrop results in sustained 20%+ annual revenue growth and significant P/E multiple expansion, pushing the stock to new highs as its market capitalization reflects its dominance in the future of surgery.

2.2. Bear Case

Increased competition from well-funded rivals like Medtronic and Johnson & Johnson proves more effective than anticipated, leading to significant pricing pressure on systems and instruments. A global economic slowdown or recession forces hospitals to slash capital budgets, causing a sharp decline in new system placements and a slowdown in procedure growth. Unexpected clinical trial setbacks for new applications or instruments, coupled with increased regulatory scrutiny of robotic surgery's cost-effectiveness, erode investor confidence. This confluence of competitive, macroeconomic, and regulatory pressures leads to margin compression, downward earnings revisions, and a severe contraction of the stock's high valuation multiple, resulting in a prolonged period of underperformance or decline.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 528Thinking Tokens: 2,494Response Tokens: 8,249Total Tokens: 11,271
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.